Septerna (SEPN) Revenue & Revenue Breakdown
Septerna Revenue Highlights
Latest Revenue (Y)
$45.95M
Latest Revenue (Q)
$26.52M
Septerna Revenue by Period
Septerna Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $45.95M | 4174.51% |
| 2024-12-31 | $1.07M | 611.92% |
| 2023-12-31 | $151.00K | 100.00% |
| 2022-12-31 | - | - |
Septerna generated $45.95M in revenue during NA 2025, up 4174.51% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Septerna Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $26.52M | 9.97% |
| 2025-12-31 | $24.12M | 12.20% |
| 2025-09-30 | $21.50M | 17963.03% |
| 2025-06-30 | $119.00K | -45.66% |
| 2025-03-31 | $219.00K | 3.30% |
| 2024-12-31 | $212.00K | 20.45% |
| 2024-09-30 | $176.00K | -52.43% |
| 2024-06-30 | $370.00K | 16.72% |
| 2024-03-31 | $317.00K | 168.64% |
| 2023-12-31 | $118.00K | 257.58% |
| 2023-09-30 | $33.00K | - |
Septerna generated $26.52M in revenue during Q1 2026, up 9.97% compared to the previous quarter, and up 12510.85% compared to the same period a year ago.
Septerna Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.72B | $636.50M |
| NRIX | Nurix Therapeutics | $83.98M | $6.25M |
| KURA | Kura Oncology | $67.48M | $18.27M |
| TNGX | Tango Therapeutics | $62.38M | - |
| MRVI | Maravai LifeSciences | $49.87M | $65.84M |
| SEPN | Septerna | $45.95M | $26.52M |
| EYPT | EyePoint Pharmaceuticals | $31.37M | $696.00K |
| ABUS | Arbutus Biopharma | $14.08M | $179.13M |
| PRME | Prime Medicine | $4.63M | - |
| PROK | ProKidney | $893.00K | $226.00K |
| BCAX | Bicara Therapeutics | - | - |